Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Nature reviews. Drug discovery

• Publication date

  2014-05-16

• Fields of study

  Medicine, Business

• Identifiers
  DOI 10.1038/nrd4309PMID 24833294
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).

  2013cited by this paper
• Does size matter in R&D productivity? If not, what does?

  2013cited by this paper
• Genomic responses in mouse models poorly mimic human inflammatory diseases

  2013cited by this paper
• Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.

  2013cited by this paper
• Model-based drug discovery: implementation and impact.

  2013cited by this paper
• Trial Watch: Phase II and Phase III attrition rates 2011–2012

  2013cited by this paper
• Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

  2012cited by this paper
• A randomized, double‐blind, placebo‐controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

  2012cited by this paper
• Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.

  2012cited by this paper
• Drug-mediated toxicity: illuminating the 'bad' in the test tube by means of cellular assays?

  2012cited by this paper
• From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment

  2012cited by this paper
• Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

  2012cited by this paper
• 5th Conference Clinical Trials on Alzheimer’s Disease

  2012cited by this paper
• Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.

  2012cited by this paper
• A Randomized Trial

  2012cited by this paper
• Lebrikizumab in the personalized management of asthma

  2012cited by this paper
• Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

  2012cited by this paper
• Experimental medicine model shows no depressogenic effects of varenicline

  2012cited by this paper
• Diagnosing the decline in pharmaceutical R&D efficiency

  2012cited by this paper
• The productivity crisis in pharmaceutical R&D

  2011cited by this paper
• Lebrikizumab treatment in adults with asthma.

  2011cited by this paper
• Pharmacological Characterization of MK-7246, a Potent and Selective CRTH2 (Chemoattractant Receptor-Homologous Molecule Expressed on T-Helper Type 2 Cells) Antagonist

  2011cited by this paper
• Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches?

  2011cited by this paper
• Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo

  2011cited by this paper
• Market withdrawal of new molecular entities approved in the United States from 1980 to 2009

  2011cited by this paper
• Evidence for ordering of Alzheimer disease biomarkers.

  2011cited by this paper
• In-vitro assessment of platelet function.

  2011cited by this paper
• The benefits and limitations of animal models for translational research in neurodegenerative diseases

  2010cited by this paper
• Prevention: Neuropsychiatric adverse effects signal the end of the line for rimonabant

  2010cited by this paper
• Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

  2010cited by this paper
• The translatability of animal models for clinical development: biomarkers and disease models.

  2010cited by this paper
• CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial

  2010cited by this paper
• How to improve R&D productivity: the pharmaceutical industry's grand challenge

  2010cited by this paper
• Of Mice and Humans: Are They the Same?—Implications in Cancer Translational Research

  2010cited by this paper
• Impact and prevalence of safety pharmacology-related toxicities throughout the pharmaceutical life cycle

  2010cited by this paper
• Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate.

  2010cited by this paper
• Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation

  2010cited by this paper
• Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats

  2010cited by this paper
• Glutamate Based Antidepressants : 20 Years On

  2009cited by this paper
• Glutamate-based antidepressants: 20 years on.

  2009cited by this paper
• Assessing the translatability of drug projects: what needs to be scored to predict success?

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists

  2009cited by this paper
• IL-13:a promising therapeutic target for bronchial asthma

  2009cited by this paper
• Lessons from 60 years of pharmaceutical innovation

  2009cited by this paper
• A prostaglandin D2 receptor antagonist modifies experimental asthma in sheep

  2009cited by this paper
• A Meta-Analysis

  2009cited by this paper
• CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation.

  2008cited by this paper
• The Use of Imaging in the Early Development of Neuropharmacological Drugs: A Survey of Approved NDAs

  2008cited by this paper
• Drug development for CNS disorders: strategies for balancing risk and reducing attrition

  2007cited by this paper
• [Clarification of the pathogenesis and development of clinical examination for allergic diseases].

  2007influential reference
• Clinical attrition due to biased preclinical assessments of potential efficacy.

  2007cited by this paper
• The sequence of events that underlie quantal transmission at central glutamatergic synapses

  2007cited by this paper
• Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

  2007cited by this paper
• Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

  2007cited by this paper
• IL-13: a promising therapeutic target for bronchial asthma.

  2006cited by this paper
• Negative association between the chemokine receptor CCR5-Δ32 polymorphism and rheumatoid arthritis: a meta-analysis

  2006cited by this paper
• Microarray-based identification of novel biomarkers in asthma.

  2006cited by this paper
• A CCR-5 antagonist inhibits the development of adjuvant arthritis in rats.

  2006cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5.

  2005cited by this paper
• Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.

  2005cited by this paper
• In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.

  2005cited by this paper
• Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor

  2004cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• The statin wars

  2003cited by this paper
• The stain wars.

  2003cited by this paper
• Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.

  2003cited by this paper
• Neuropsychopharmacology : The Fifth Generation of Progress

  2002cited by this paper
• The industrialization of drug discovery.

  2002cited by this paper
• Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751.

  2001cited by this paper
• Prostaglandin D2 as a mediator of allergic asthma.

  2000cited by this paper
• Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

  2000cited by this paper
• Antidepressant effects of ketamine in depressed patients.

  2000influential reference
• Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics.

  1999cited by this paper
• Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block.

  1999cited by this paper
• [Apolipoprotein E polymorphism and Alzheimer disease].

  1996cited by this paper
• Apolipoprotein E polymorphism and Alzheimer's disease.

  1993cited by this paper
• A RANDOMISED CLINICAL TRIAL

  1989cited by this paper
• [20 YEARS].

  1965cited by this paper

• Breathing lung-on-chip: a versatile tool for assessing respiratory toxicity across multiple therapeutic modalities.

  2026cites this paper
• Next-generation lung-cancer-on-a-chip: toward personalized therapy, AI, and CRISPR-driven models.

  2026cites this paper
• Antiviral drug discovery and development: challenges and future directions

  2026cites this paper
• Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitors.

  2026cites this paper
• Nanomedicines Reshape the Tumor Microenvironment: Multidimensional Strategies from Modulating “Barriers” to Metabolic Intervention

  2026cites this paper
• An integrated drug repositioning analysis identifies rosiglitazone as a treatment for sarcopenia.

  2026cites this paper
• Toward Integrative Predictive Toxicology: Advanced Methods for Drug Toxicity and Safety Prediction

  2026cites this paper
• Innovations in skin microphysiological systems for nonclinical testing and FDA modernization

  2026cites this paper
• Delivery science: Its increasing importance for the next generation of medicines.

  2026cites this paper
• Computer-Aided Discovery of Drugs Against Chagas Disease.

  2026cites this paper
• Evaluation of Drug-Induced Kidney Injury by Primary Culture of Rat Kidney Tissue Slices Using Oxygen-Permeable Polyolefin Plate with Low Drug Adsorption.

  2026cites this paper
• Mechanical signatures and models of the bone marrow niche

  2025cites this paper
• Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges.

  2025cites this paper
• Tellurophene-Tagged Carfilzomib Enables Single-Cell Mass Cytometric Mapping of Proteasome Activity.

  2025cites this paper
• Points to consider for revising the ICH S7A guideline on safety and secondary pharmacology.

  2025cites this paper
• The Role of Cross-Institutional and Interdisciplinary Collaboration in Defining and Executing a Quantitative Systems Pharmacology Strategy.

  2025cites this paper
• Drug target assessments: classifying target modulation and associated health effects using multi-level BERT-based classification models

  2025cites this paper
• Genomics of drug target prioritization for complex diseases

  2025cites this paper
• Mapping the developmental path for Parkinson’s disease therapeutics

  2025cites this paper
• In silico evaluation of the estrogenic activity of flavonoids from Butea monosperma: Exploring phytoestrogenic alternatives to endogenous estrogens

  2025cites this paper
• Innovation versus Financialization in the US Pharmaceutical Industry

  2025cites this paper
• Use of new approach methodologies (NAMs) in epilepsy research and seizure risk assessment.

  2025cites this paper
• Proof-of-Concept of a DNA-Based Recording System for High-Throughput Functional Gene Screening

  2025cites this paper
• The differentiation state of small intestinal organoid models influences prediction of drug-induced toxicity

  2025cites this paper
• Applying the 3Rs to urinalysis assessments in toxicity studies: refining procedures and adopting a case-by-case approach

  2025cites this paper
• Comparative Analysis of Proximal Tubule Cell Sources for In Vitro Studies of Renal Proximal Tubule Toxicity

  2025cites this paper
• Therapeutic potential of targeting ubiquitin-specific proteases in colorectal cancer.

  2025cites this paper
• Biomarker-guided decision making in clinical drug development for neurodegenerative disorders

  2025cites this paper
• Pharmacophore-based virtual screening and in silico investigations of small molecule library for discovery of human hepatic ketohexokinase inhibitors for the treatment of fructose metabolic disorders

  2025cites this paper
• DILI prediction in drug development: present and future

  2025cites this paper
• Characterization of the toxicological findings from 90-day and 2-year repeated-dose toxicity studies of pesticides in rats.

  2025cites this paper
• Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety

  2025cites this paper
• Estrogen receptor β deficiency increases the susceptibility to ulcerative colitis by inducing mitochondrial fission and consequently accelerating senescence of colonic epithelial cells

  2025cites this paper
• The technological re-engineering of pharmaceutical Research and Development: A quantitative analysis of innovation's impact on the drug discovery value chain

  2025cites this paper
• Genetic insights into the therapeutic potential of hydrogen sulfide.

  2025cites this paper
• Traversing the Valley of Death for nanotechnology-based natural products: strategies and insights from pharmaceutical stakeholders

  2025cites this paper
• Therapeutic approaches for liver fibrosis/cirrhosis by targeting pyroptosis

  2025cites this paper
• The "five-star matrix" for patient-centric drug discovery and development in neuroscience.

  2025cites this paper
• Advanced cardiotoxicity profiling using field potential imaging with UHD-CMOS-MEA in human iPSC-derived cardiomyocytes

  2025cites this paper
• Advancing Target Discovery Through Disease-Specific Integration of Multi-Modal Target Identification Models and Comprehensive Target Benchmarking System

  2025cites this paper
• Cytochrome P450 inhibition correlates with hepatotoxicity of pesticides: Analysis using repeated-dose toxicity data in rats.

  2025cites this paper
• Implementation of a data science and artificial intelligence strategy across pharmaceutical R&D: challenges and solutions.

  2025cites this paper
• High Content Image Analysis of Cellular Responses of the Murine J774A.1 Cell Line and Primary Human Cells Alveolar Macrophages to an Extended Panel of Pharmaceutical Agents

  2025cites this paper
• Using human genomics to validate drug targets for acute ischemic stroke.

  2025cites this paper
• Proposed Key Characteristics of Neurotoxic Chemicals.

  2025cites this paper
• Computer Aided Drug Design for Enhanced Drug Discovery and Development Processes

  2025cites this paper
• RXFP1, the relaxin receptor: Lost and found in translation.

  2025cites this paper
• Current practices on the measurement of electrocardiogram and hemodynamic parameters in non-rodent species in regulatory safety assessment studies.

  2025cites this paper
• Nanomaterials targeting cancer stem cells to overcome drug resistance and tumor recurrence

  2025cites this paper
• Challenges and Opportunities in Combining Ultrasound and Inductive Coupling for Energy Supply and Bidirectional Data Exchange in Bioelectronics Medicine Implant Networks

  2025cites this paper
• Computational modelling for improved translation of cardiac inotropic and lusitropic drug effects from rats to humans

  2025cites this paper
• Advances in liver organoids: replicating hepatic complexity for toxicity assessment and disease modeling

  2025cites this paper
• Franchise Data Strategy: “PIVOT”ing From Cognitive Dissonance Toward Making What Is Implicit, Explicit

  2025cites this paper
• Large-Scale Compartmental Model-Based Study of Preclinical Pharmacokinetic Data and Its Impact on Compound Triaging in Drug Discovery.

  2025cites this paper
• Synergistic drug combination screening using a nanodroplet processing platform to enhance neuroblastoma treatment in TH‐MYCN transgenic mice

  2025cites this paper
• Best Practices and Recommendations for Non-Liquid Matrices Bioanalysis

  2025cites this paper
• Non-Invasive Quantification of Viability in Spheroids Using Deep Learning

  2025cites this paper
• Quantitative Systems Pharmacology Development and Application in Neuroscience.

  2025cites this paper
• Discovering a predictive metabolic signature of drug-induced structural cardiotoxicity in cardiac microtissues

  2025cites this paper
• INSIGHT: In Silico Drug Screening Platform using Interpretable Deep Learning Network

  2025cites this paper
• When the drugs (don’t) work: The role of science in product commercialization

  2025cites this paper
• Association between drug-induced heart failure and CYP1A1, CYP1B1, and CYP3A4 inhibition: Utility of cytochrome P450 inhibition assay for evaluating cardiotoxicity of drug candidates.

  2025cites this paper
• Cardiac physiological changes induced by cardiovascular drugs from different chemical classes in zebrafish mirrored in mice: A predictive tool for comprehensive risk assessment

  2025cites this paper
• Advancing Employability in Cambodia: The Synergistic Effects of Training, Adaptability, and Organizational Culture

  2025cites this paper
• Adverse Outcome Pathway and Machine Learning to Predict Drug Induced Seizure Liability.

  2025cites this paper
• Quantitative and qualitative concordance between clinical and nonclinical toxicity data.

  2025cites this paper
• Target Engagement Assays in Early Drug Discovery

  2025cites this paper
• Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury

  2025cites this paper
• Chemical-induced heart defects using a transgenic zebrafish model

  2025cites this paper
• Current status and future prospects of toxicity assessment using organoids

  2025cites this paper
• Multiomics in atherosclerotic cardiovascular disease.

  2025cites this paper
• Strengths, Weaknesses, Opportunities, and Potential Threat Analysis of Targeting Leucine-Rich Repeat Kinase 2 for Parkinson's Disease Treatment: Status Quo and Quo Vadis.

  2025cites this paper
• Capturing Unanticipated Drug Toxicities Using an Ensemble Machine Learning Approach

  2025cites this paper
• Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern

  2025cites this paper
• Gene and genetic therapies in Alzheimer’s disease and other dementias

  2025cites this paper
• Cancer nanomedicine: Concepts, promises, and challenges

  2025cites this paper
• Substituted 2-pyrrolinone compounds as inhibitors of B-cell activating factor (BAFF) for autoimmune diseases treatment.

  2025cites this paper
• Explainable Artificial Intelligence: A Perspective on Drug Discovery

  2025cites this paper
• MSstatsTMT Improves Accuracy of Thermal Proteome Profiling

  2025cites this paper
• Development of a genetic priority score to predict drug side effects using human genetic evidence

  2025influential citation
• An in silico study on phytochemicals from Hibiscus rosa-sinensis as potential inhibitors of SARS-CoV-2 3CLpro

  2025cites this paper
• Incentivizing Information Exchange Within Groups: The Role of Voting Protocols in U.S. Food and Drug Administration Advisory Committees

  2025cites this paper
• Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio.

  2025cites this paper
• Drug toxicity prediction based on genotype-phenotype differences between preclinical models and humans

  2025cites this paper
• Trialblazer: A chemistry-focused predictor of toxicity risks in late-stage drug development.

  2025cites this paper
• Forecasting clinical trial success using anonymized external expert panels.

  2025cites this paper
• A comparative computational analysis of IFN-alpha pharmacokinetics and its induced cellular response in mice and humans

  2025cites this paper
• Accelerating drug development at Bristol Myers Squibb through innovation.

  2024cites this paper
• Target identification and validation in research

  2024cites this paper
• Low-frequency and rare genetic variants associated with rheumatoid arthritis risk

  2024cites this paper
• Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations

  2024cites this paper
• Immunoaffinity proteomics for kidney injury biomarkers in male beagle dogs

  2024cites this paper
• Electrophysiological Changes in the Rabbit Ventricular Wedge and Human-Induced Pluripotent Stem-Cell Derived (IPSC) Cardiomyocytes Translate to Severe Arrhythmia Observed in a Canine Toxicology Study, Not Predicted by Standard In Vitro Ion Channel Assays

  2024cites this paper
• What does it take to make progress in a disease?

  2024cites this paper
• Development of a human genetics-guided priority score for 19,365 genes and 399 drug indications

  2024cites this paper
• The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability

  2024cites this paper
• Population-specific variations in KCNH2 predispose patients to delayed ventricular repolarization upon dihydroartemisinin-piperaquine therapy

  2024cites this paper
• Bias translation: The final frontier?

  2024cites this paper
• Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury

  2024cites this paper
• Neuroimaging biomarkers for drug discovery and development in Schizophrenia.

  2024cites this paper